Cypherpunk Technologies Inc. (NASDAQ: CYPH)

Cypherpunk Technologies Inc. is a privacy technology company that also operates a biopharmaceutical subsidiary focused on developing antibody therapies for cancer. The firm was originally incorporated as Leap Therapeutics Inc and changed its name to Cypherpunk Technologies Inc in November 2025 to reflect its strategic shift toward acquiring Zcash and advancing privacy preserving technologies. Its core mission is to advance technologies that guarantee privacy for individuals on the internet while its subsidiary Leap Therapeutics pursues novel treatments targeting disease related proteins. The company combines a digital asset treasury strategy centered on Zcash with preclinical and clinical research programs in oncology. As of the filing date, Cypherpunk held approximately 294,743 ZEC tokens representing about 1.76% of the total circulating supply of the Zcash network.

The company does not yet generate revenue from product sales because its therapeutic candidates remain in clinical or preclinical stages and its privacy technology initiatives are primarily investment focused. Capital is raised through equity offerings, such as the $58.88 million private placement completed in October 2025, which funds both the digital asset treasury and research activities. Holdings of Zcash (ZEC) are maintained as a non operating investment and are not reported as revenue. The firm has not paid any royalties to its licensor Eli Lilly or to its collaboration partner Adimab as of the reporting date. No commercial product has been launched and therefore no sales or service revenue is recognized.

In the privacy technology sector, Cypherpunk positions itself as the only publicly traded company whose core mission is the advancement of privacy enhancing technologies, distinguishing it from firms that treat digital assets solely as speculative investments. Its competitive advantages include early stage accumulation of Zcash, direct involvement in the Zcash ecosystem through investments in wallet development, and a clear focus on regulatory compliant privacy solutions. Major competitors in the digital asset space include pure play bitcoin investment vehicles, other privacy coins such as Monero and Dash, and exchange traded products like the Grayscale Zcash Trust that provide indirect exposure to ZEC. In the biopharmaceutical arena, the subsidiary Leap Therapeutics competes with large oncology companies such as Merck, Pfizer, Novartis and AstraZeneca, leveraging its proprietary anti DKK1 antibody platform and its partnership with Adimab to differentiate its pipeline. The company’s dual focus strategy aims to capture value from both the growing demand for financial privacy and the unmet need in cancer therapeutics.

Cypherpunk privacy technology initiatives serve individuals and institutions seeking confidential financial transactions, including retail users of Zcash and institutional investors interested in privacy focused digital assets. Through Leap Therapeutics, the company targets patients, hospitals and oncology clinics that require advanced therapies for colorectal cancer and related indications. The firm also engages with research organizations and clinical trial sites to advance its drug development programs. No specific customer names are disclosed in the filing.